rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Coya Therapeutics, Inc.

COYA · Nasdaq

Health CareBiotechnologyNot moving yet

COYA stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 9.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
56 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$103KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders56+2 on the quarter
New · exited8 · 6
Reported value$45.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
DME Capital Management, LPunchanged · filed 14 Aug 20262,335,540$13.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026842,220$4.9M-2,693−0.3%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026800,000$4.7M00.0%
AIGH Capital Management LLCreduced · filed 7 Aug 2026631,912$3.7M-343,492−35.2%
CM Management, LLCadded · filed 13 Aug 2026400,000$2.3M+25,000+6.7%
PRIVATE MANAGEMENT GROUP INCadded · filed 31 Jul 2026384,217$2.2M+15,121+4.1%
MARSHALL WACE, LLPadded · filed 13 Aug 2026249,793$1.5M+24,001+10.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026228,243$1.3M-5,159−2.2%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026192,986$1.1M+89,022+85.6%
Prosight Management, LPreduced · filed 14 Aug 2026170,000$995K-250,360−59.6%
31 Mar 2023 – 30 Jun 2026
83255Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Mark H. Pavao Company insiderDirector · last 9 Apr 20260 · 0
Arun Swaminathan Company insiderChief Executive Officer · last 22 Jan 20262 · 0
David S. Snyder Company insiderChief Financial Officer · last 22 Jan 20262 · 0
Fred Grossman Company insiderChief Medical Officer · last 22 Jan 20261 · 0
Howard Berman Company insiderExecutive Chairman · last 22 Jan 20261 · 0
Anabella Villalobos Company insiderDirector · last 2 Jan 20261 · 0
Ann Lee Company insiderDirector · last 2 Jan 20262 · 0
Dieter Weinand Company insiderDirector · last 2 Jan 20260 · 0
Dov A. Goldstein Company insiderDirector · last 2 Jan 20261 · 0
Wilbur L. Ross Jr. Company insiderDirector · last 2 Jan 20260 · 0
Hideki Garren Company insiderDirector · last 1 Jan 20241 · 0
Adrian Hepner Company insiderChief Medical Officer · last 27 Feb 20231 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-284%
Return on capital employedFY 2025 · to 31 Dec 2025-51.2%
Share count trendFY 2025 · to 12 Mar 202612.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$46.8M

Analyst forecasts

No analyst forecasts yet.